All In Biotech

Drug Trial Radar · NCT06771063

A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients

A Multicenter, Randomized, Double-blind, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of WXSH0102 Tablets in the Treatment of Vulvovaginal Candidiasis (VVC)

Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Jan 13, 2025

Primary completion

Jul 10, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Cisen Pharmaceutical CO., LTD.Industry
Sponsor type
Industry
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, active-controlled, dose-ranging clinical trial designed to evaluate the efficacy and safety of the investigational drug compared to the active comparator in the treatment of vulvovaginal candidiasis. The trial consists of three phases: screening/enrollment (D-3 to D-1), treatment period (D1 to D3), and follow-up period (D4, D11±2, D25±3). Eligible subjects in this study will be randomized in a 1:1:1:1 ratio to three investigational drug arms with different dosing regimens and one active control arm. Specifically, Group A will receive WXSH0102 tablets with 1400 mg on the first day followed by a maintenance dose of 700 mg for two consecutive days, Group B will receive WXSH0102 tablets with 1000 mg on the first day followed by a maintenance dose of 500 mg for two consecutive days, Group C will receive WXSH0102 tablets with 600 mg on the first day followed by a maintenance dose of 300 mg for two consecutive days, and Group D (active control group) will receive fluconazole capsules for only one day on D1. All medications will be administered orally.

Conditions

  • Vaginitis

Interventions

  • WXSH0102/placeboDrug

    Administer WXSH0102 tablets/placebo orally.

  • fluconazole capsules/placeboDrug

    Administer fluconazole capsules/placebo orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving cure at the D11±2 visit.Time frame: day 11±2

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • 251 Yaojiayuan Road, Chaoyang District, Beijing

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Obstetrics and Gynecology Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.